Clinical Trial Update: Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of CHR-2797 in combination with erlotinib for locally advanced or metastatic non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CHR-2797 (CHR-2797)
• Tarceva (erlotinib)

Snippet

Sponsor: Chroma Therapeutics | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: TERMINATED